基石藥業(02616.HK)合作夥伴治療胃腸間質瘤藥物臨床顯示耐受性良好
基石藥業(02616.HK)公布,合作夥伴Blueprint Medicines於6月29日宣布「柳葉刀腫瘤學」發表了NAVIGATOR臨床試驗結果,資料顯示avapritinib用於PDGFRA D842V突變型晚期胃腸間質瘤(GIST)患者,24個月的總生存率達到81%,且耐受性良好。
Blueprint Medicines已與基石藥業達成獨家合作及授權授權合約,在中國內地和香港特別行政區、澳門特別行政區及台灣地區推進avapritinib、fisogatinib和pralsetinib 的研發和商業化。Blueprint Medicines將保留以上相關產品在全球其他國家/地區的研發和商業化權利。
avapritinib是一種已獲美國食品和藥品監督管理局批准的激(酉每)抑制劑,用於治療攜帶PDGFRA外顯子18突變的不可切除或轉移GIST成人患者。avapritinib尚未被當局批准於美國用於治療任何其他適應症,且尚未被其他地區健康監管部門批准用於任何適應症。Blueprint Medicines正在全球範圍進行avapritinib治療晚期、冒煙型和惰性系統性肥大細胞增多症的臨床研發。(ek/k)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.